EPO and Hyperglycemia: Moreover, we did not evaluate some neonatal factors [38] because of their low (i.e: inhaled nitric oxide, erythropoietin, and dopamine treatment, hyperglycemia) or high (i.e.: caffeine treatment) occurrence in our population (unreported data) which did not allow comparisons between groups and evaluation of their possible effect.